AstraZeneca PLC has grown revenue 9.8% a year over three years and 17% a year over five, with earnings per share compounding at 46%. Revenue growth, 3-year annual rate: +9.8% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: +17%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +46%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 11, FY2015 to FY2025, as filed.

AZNAstraZeneca PLC

Healthcare

$159.19+5.4% 1Y

$159.19

$145.5452 weeks$208.62

Is it growing?

Good

Operating margin widening (+3.2 points). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

Margin direction+3.2 points operatingSEC EDGAR · Jun 30, 2025

Trailing-twelve-month operating margin, 25.7% now against 22.5% a year earlier.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is AZN growing?

AstraZeneca PLC has grown revenue 9.8% a year over three years and 17% a year over five, with earnings per share compounding at 46%.

+9.8%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · steady growth, ahead of inflation · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +17%
Revenue growth, 5-year rate · +9.8% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +46%
Earnings per share, 3-year rate · revenue +9.8% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed